RATIONALE: Human rhinoviruses (HRV) are the leading cause of upper respiratory infections and have been postulated to trigger asthma exacerbations. However, whether HRV are detected during crises because upper respiratory infections often accompany asthma attacks, or because they specifically elicit exacerbations, is unclear. Moreover, although several hypotheses have been advanced to explain virus-induced exacerbations, their mechanism remains unclear. OBJECTIVES: To determine the role of HRV in pediatric asthma exacerbations and the mechanisms mediating wheezing. METHODS: We prospectively studied 409 children with asthma presenting with upper respiratory infection in the presence or absence of wheezing. Candidate viral and immune mediators of illness were compared among children with asthma with different degrees of severity of acute asthma. MEASUREMENTS AND MAIN RESULTS: HRV infections specifically associated with asthma exacerbations, even after adjusting for relevant demographic and clinical variables defined a priori (odds ratio, 1.90; 95% confidence interval, 1.21-2.99; P = 0.005). No difference in virus titers, HRV species, and inflammatory or allergic molecules was observed between wheezing and nonwheezing children infected with HRV. Type III IFN-λ(1) levels were higher in wheezing children infected with HRV compared with nonwheezing (P < 0.001) and increased with worsening symptoms (P < 0.001). Moreover, after adjusting for IFN-λ(1), children with asthma infected with HRV were no longer more likely to wheeze than those who were HRV-negative (odds ratio, 1.18; 95% confidence interval, 0.57-2.46; P = 0.66). CONCLUSIONS: Our findings suggest that HRV infections in children with asthma are specifically associated with acute wheezing, and that type III IFN-λ(1) responses mediate exacerbations caused by HRV. Modulation of IFN- λ(1) should be studied as a therapeutic target for exacerbations caused by HRV.
RATIONALE: Human rhinoviruses (HRV) are the leading cause of upper respiratory infections and have been postulated to trigger asthma exacerbations. However, whether HRV are detected during crises because upper respiratory infections often accompany asthma attacks, or because they specifically elicit exacerbations, is unclear. Moreover, although several hypotheses have been advanced to explain virus-induced exacerbations, their mechanism remains unclear. OBJECTIVES: To determine the role of HRV in pediatric asthma exacerbations and the mechanisms mediating wheezing. METHODS: We prospectively studied 409 children with asthma presenting with upper respiratory infection in the presence or absence of wheezing. Candidate viral and immune mediators of illness were compared among children with asthma with different degrees of severity of acute asthma. MEASUREMENTS AND MAIN RESULTS:HRV infections specifically associated with asthma exacerbations, even after adjusting for relevant demographic and clinical variables defined a priori (odds ratio, 1.90; 95% confidence interval, 1.21-2.99; P = 0.005). No difference in virus titers, HRV species, and inflammatory or allergic molecules was observed between wheezing and nonwheezing children infected with HRV. Type III IFN-λ(1) levels were higher in wheezingchildren infected with HRV compared with nonwheezing (P < 0.001) and increased with worsening symptoms (P < 0.001). Moreover, after adjusting for IFN-λ(1), children with asthma infected with HRV were no longer more likely to wheeze than those who were HRV-negative (odds ratio, 1.18; 95% confidence interval, 0.57-2.46; P = 0.66). CONCLUSIONS: Our findings suggest that HRV infections in children with asthma are specifically associated with acute wheezing, and that type III IFN-λ(1) responses mediate exacerbations caused by HRV. Modulation of IFN- λ(1) should be studied as a therapeutic target for exacerbations caused by HRV.
Authors: G P Rakes; E Arruda; J M Ingram; G E Hoover; J C Zambrano; F G Hayden; T A Platts-Mills; P W Heymann Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: Robin Stephens; David A Randolph; Guangming Huang; Michael J Holtzman; David D Chaplin Journal: J Immunol Date: 2002-11-15 Impact factor: 5.422
Authors: P Sheeran; H Jafri; C Carubelli; J Saavedra; C Johnson; K Krisher; P J Sánchez; O Ramilo Journal: Pediatr Infect Dis J Date: 1999-02 Impact factor: 2.129
Authors: M M Pizzichini; E Pizzichini; A Efthimiadis; A J Chauhan; S L Johnston; P Hussack; J Mahony; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1998-10 Impact factor: 21.405
Authors: Y-P Liu; V Rajamanikham; M Baron; S Patel; S K Mathur; E A Schwantes; C Ober; D J Jackson; J E Gern; R F Lemanske; J A Smith Journal: Clin Exp Allergy Date: 2017-03 Impact factor: 5.018
Authors: Tess M Becker; Sandy R Durrani; Yury A Bochkov; Mark K Devries; Victoria Rajamanickam; Daniel J Jackson Journal: Ann Allergy Asthma Immunol Date: 2013-08-28 Impact factor: 6.347
Authors: Kazuyuki Nakagome; Yury A Bochkov; Shamaila Ashraf; Rebecca A Brockman-Schneider; Michael D Evans; Thomas R Pasic; James E Gern Journal: J Allergy Clin Immunol Date: 2014-03-14 Impact factor: 10.793
Authors: Vishal Parikh; Jacqueline Scala; Riva Patel; Corinne Corbi; Dennis Lo; Yury A Bochkov; Joshua L Kennedy; Richard C Kurten; Stephen B Liggett; James E Gern; Cynthia J Koziol-White Journal: Am J Respir Cell Mol Biol Date: 2020-03 Impact factor: 6.914
Authors: A Głobińska; M Pawełczyk; A Piechota-Polańczyk; A Olszewska-Ziąber; S Moskwa; A Mikołajczyk; A Jabłońska; P K Zakrzewski; M Brauncajs; M Jarzębska; S Taka; N G Papadopoulos; M L Kowalski Journal: Clin Exp Immunol Date: 2016-11-14 Impact factor: 4.330